Global cord blood corporation reports financial results for the second quarter and first half of fiscal 2022

Added 19,066 new subscribers in 2q22 revenues up 9.8% yoy to rmb313.7 million ($48.7 million)         gross profit up 11.0% yoy to rmb267.5 million ($41.5 million) operating income up 15.3% yoy to rmb160.5 million ($24.9 million) non-gaap operating income up 14.1% yoy to rmb172.8 million ($26.8 million) conference call to be held on november 26, 2021, at 8:00 a.m. et hong kong, nov. 24, 2021 /prnewswire/ -- global cord blood corporation (nyse: co) ("gcbc" or the "company"), china's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the second quarter and first half of fiscal 2022 ended september 30, 2021.
CO Ratings Summary
CO Quant Ranking